Price Chart

Profile

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (“MRD”) in patients with multiple myeloma (“MM”), B cell acute lymphoblastic leukemia (“ALL”) and chronic lymphocytic leukemia (“CLL”) and is also available as a CLIA-validated laboratory developed test (“LDT”) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (“DLBCL”).
URL https://www.adaptivebiotech.com
Investor Relations URL https://investors.adaptivebiotech.com/
HQ State/Province Washington
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (“MRD”) in patients with multiple myeloma (“MM”), B cell acute lymphoblastic leukemia (“ALL”) and chronic lymphocytic leukemia (“CLL”) and is also available as a CLIA-validated laboratory developed test (“LDT”) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (“DLBCL”).
URL https://www.adaptivebiotech.com
Investor Relations URL https://investors.adaptivebiotech.com/
HQ State/Province Washington
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A